Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer

Southern Medical Journal

Volumn 97, Issue 9, 2004, Pages 831-835

  LaRocca, Renato V ^a   Glisson, Shawn D ^a   Hargis, Jeffrey B ^a   Kosfeld, Rodney E ^a   Leaton, Karen E ^a   Hicks, Rebecca M ^a   Amin Zimmerman, Falguni ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

Bolus 5 fluorouracil leucovorin; Colorectal cancer; Compassionate use study; Diarrhea; Oxaliplatin; Pretreated

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMED CONSENT; LARYNGOPHARYNGEAL DYSESTHESIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREMEDICATION; THROAT DISEASE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 4544322112     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000129793.35088.5C     Document Type: Article

References (32)

1. American Cancer Society. Cancer facts and figures, 2001. Atlanta, ACS, 2001 (publication no. 5008.01).
2. Bleiberg H, and de Gramont A. Oxaliplatin plus 5-FU: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998;25: 32-39.
3. Rustum YM, Cao S, Zhang Z. Rationale for treatment design: biochemical modulation of 5-Fluorouracil by leucovorin. Cancer J Sci Am 1998; 4:12-18.
4. Saltz L, Douillard J, Pirotta N, et al. Irinotecan plus Fluorouracil/Leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001;6:81-91.
5. Cvitkovic E. A historical perspective on oxaliplatin: rethinking the role of platinum compounds and learning from near misses. Semin Oncol 1998;25:Suppl 5:1-3.
6. Khayat D, Gil-Delgado M, Antoine E, et al. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Oncology 2001;April:415-434.
7. Raymond E, Faivre S, Woynarowski J, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Seminars in Oncology 1998;25:Suppl 5:4-12.
8. Raymond E, Chaney SG, Taama A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
9. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996;52:1855-1865.
10. Hills CA, Kelland LR, Abel G, et al. Biological properties of ten human ovarian cell lines: calibration in vitro against four platinum complexes. Br J Cancer 1989;59:527-534.
11. Behrens SC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987;47: 414-418.
12. Teicher BA, Holden SA, Herman TS, et al. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Intern J Cancer 1991;47:252-260.
13. Balconi G, Pang Y, Broggini M, et al. Cis-dichlorodiammineplatinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. Br J Cancer 1971;64:288-292.
14. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 1987;47:2056-2061.
15. Brienza S, Bensmaine M, Soulie P, et al. Oxaliplatin added to 5-FU-based therapy in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol 1999;10:1311-1316.
16. Martoni A, Mini E, Pinto C, et al. Oxaliplatin and protracted continuous 5-FU infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol 2001;12:519-524.
17. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-Fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999;35:1338-1342.
18. Mathe G, Kidani Y, Eriguchi M, et al. Antitumor activity of a new platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother 1989;43:237-250.
19. Tashiro T, Kawada Y, Sakurai Y, et al. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother 1989;43:251-260.
20. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland), World Health Organization Offset Publication, 1979, p 48.
21. Cancer Therapy Evaluation Program Common Toxicity Criteria, Version 2.0 DCTC, NCI, NIH, DHHS. March 1998.
22. Levi F, Perpoint B, Focan C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993;29A:1280-1284.
23. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-108.
24. Manchover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II trials in advanced colorectal carcinoma patients who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 1:95-98.
25. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568.
26. Levi F, Zidani R, Misset JL. Randomized multicenter trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350:681-686.
27. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
28. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluoruracil, with or without oxaliplatin, as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
29. Levi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy by oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal metastasis: a randomized multiinstitutional trial. J Natl Cancer Inst 1994;21: 1608-1617.
30. Lokich JJ, Ahlren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-432.
31. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
32. Hochster HS, Chachoua A, Speyer J, et al. First-line activity of oxaliplatin with weekly bolus 5-FU and low dose leucovorin in advanced colorectal cancer. Proc Am Soc Clin Oncol 2001;abstract 548.